SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices

Abstract Background Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars of heart failure (HF) pharmacological therapy. Objective The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF with reduced ejection fraction (HFrEF) in terms of atrial and v...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Valerio Mariani, Carlo Lavalle, Marta Palombi, Nicola Pierucci, Sara Trivigno, Andrea D'Amato, Domenico Filomena, Pietro Cipollone, Domenico Laviola, Agostino Piro, Silvia Prosperi, Josefina Magliolo, Vincenzo Myftari, Vincenzo Mirco La Fazia, Paolo Severino, Cristina Chimenti, Roberto Badagliacca, Carmine Dario Vizza
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:ESC Heart Failure
Subjects:
Online Access:https://doi.org/10.1002/ehf2.15223
Tags: Add Tag
No Tags, Be the first to tag this record!